No Data
No Data
Express News | Pasithea Therapeutics Announces An Independent Safety Review Committee Completes Safety Review Of Data From First Dose Cohort In Phase 1 Trial Of PAS-004
Express News | Pasithea Therapeutics Corp: Remain on Track to Present Our Initial Safety and Pharmacokinetic (Pk) Data in Q3 of 2024.
Express News | Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 Following Positive Safety Review Committee (Src) Recommendation for Pas-004 in Ongoing Phase 1 Clinical Trial
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersConcord Medical Services (NYSE:CCM) shares moved upwards by 51.9% to $1.2 during Tuesday's regular session. The market value of their outstanding shares is at $52.1 million. Annexon (NASDAQ:ANN
Express News | Pasithea Therapeutics To Present New Preclinical Data Showing PAS-004 Strongly Inhibiting NRAS Cancer Cell Lines
Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting
No Data